Reuters reported that healthcare company McKesson (NYSE:MCK) announced it would acquire privately held Precision Medicine Group for approximately $2.25 billion. This acquisition is part of McKesson's multi-year effort to strengthen its high-growth businesses, and Precision Medicine Group will become part of McKesson's oncology and multi-specialty division.